SCHEMBL13178797

SCHEMBL13178797

COc1cc(C)c(CN(C)C)cc1Cl

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A4 P31645 9/20 0.43
SLC6A2 P23975 7/20 0.43
SLC6A3 Q01959 7/20 0.43
HTR2A P28223 3/20 0.43
KCNH2 Q12809 2/20 0.43
TAAR1 Q96RJ0 1/20 0.42
HTR7 P34969 2/20 0.42
GLA P06280 1/20 0.41
TSHR P16473 1/20 0.41
HTR1A P08908 1/20 0.41
HTR1D P28221 1/20 0.41
HTR1B P28222 1/20 0.41
HTR2C P28335 1/20 0.41
HTR1E P28566 1/20 0.41
HTR2B P41595 1/20 0.41
HTR3A P46098 1/20 0.41
HTR5A P47898 1/20 0.41
HTR6 P50406 1/20 0.41
MEN1 O00255 1/20 0.41
ALDH1A1 P00352 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12467312 0.79 TAAR1 (0.46) TAAR1GLATSHRMEN1ALDH1A1
SCHEMBL14582025 0.79 MAPT (0.43) TAAR1GLATSHRMEN1ALDH1A1
SCHEMBL13178790 0.78 SLC6A4 (0.40) SLC6A4SLC6A2SLC6A3HTR2AKCNH2
SCHEMBL13178802 0.78 TAAR1 (0.53) TAAR1GLATSHRMEN1ALDH1A1
SCHEMBL16200307 0.78 PDE4A (0.47) TAAR1ALDH1A1GAANPC1
SCHEMBL19195019 0.78 TAAR1 (0.44) TAAR1GLATSHRMEN1ALDH1A1
SCHEMBL14405230 0.76 TAAR1 (0.47) TAAR1TSHRMEN1ALDH1A1KMT2A
SCHEMBL13178806 0.75 SLC6A4 (0.48) SLC6A4SLC6A2SLC6A3HTR2AKCNH2
SCHEMBL383766 0.74 GAA (0.54) TAAR1GLATSHRMEN1ALDH1A1
SCHEMBL16200298 0.72 ALDH1A1 (0.47) HTR2ATAAR1HTR7GLAHTR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1720545-B1 BICYCLIC AND BRIDGED NITROGEN HETEROCYCLES CHEMOCENTRYX INC (US) 2014-10-29 EP disclosed
US-8324216-B2 Substituted piperazines CHEMOCENTRYX, INC. (US) 2012-12-04 US disclosed
US-7790726-B2 Monocyclic and bicyclic compounds and methods of use CHEMOCENTRYX, INC. (US) 2010-09-07 US disclosed
US-7589199-B2 Substituted piperazines CHEMOCENTRYX, INC. (US) 2009-09-15 US disclosed
US-7435831-B2 Bicyclic and bridged nitrogen heterocycles CHEMOCENTRYX, INC. (US) 2008-10-14 US disclosed
US-7435830-B2 Bicyclic and bridged nitrogen heterocycles CHEMOCENTRYX, INC. (US) 2008-10-14 US disclosed
US-20070066583-A1 Monocyclic and bicyclic compounds and methods of use CHEMOCENTRYX, INC. (US) 2007-03-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070066583-A1 Monocyclic and bicyclic compounds and methods of use CCR1, CCR3, CCR4 SLC6A4 3722/4885SLC6A2 4355/4885SLC6A3 4398/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.